Press kit
Boilerplate
Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.
We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
Media contact
Owkin’s experts are available to comment on topics related to medical research and Al.
For international media requests, please contact [email protected]
For French media requests, please contact [email protected]
About our founder
Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College. He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.
FAQs
Owkin is a French-American AI startup with teams in Paris, Nantes, New York, Boston, London, Geneva and Germany.
Owkin was co-founded by Thomas Clozel, MD, a former assistant professor in clinical hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.
Owkin was founded with the belief that the future of precision health is in technologies that are able to unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way.
Owkin is differentiated by a focus on improving our fundamental understanding of disease mechanics through multimodal patient data and cutting-edge AI that is grounded in biology.
We are a full-stack AI biotech. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients.
We aim to improve the way we treat and diagnose diseases by using the latest technologies to advance fundamental scientific knowledge.
We also believe that the future of precision medicine is in technologies that are able to unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way.
By developing a cutting-edge federated learning framework while simultaneously building the world’s biggest and best network of hospitals, KOLs and high-quality, multimodal datasets, we are focused on making long-term, transformative improvements to medical research and drug development.
Owkin's founding mission is to improve medical research in a way that protects data privacy and security.
Owkin is ISO27001:2013 certified and is committed to the protection of customer information in accordance with global security requirements, as well as with applicable legal and regulatory frameworks.
Owkin relies on a set of organizational & technical measures to ensure security objectives are achieved. Internal and external audits are performed regularly and with every major changes to Owkin’s Information Systems. A Security Risk Assessment is performed on the whole organization and regularly reviewed to keep up to date in regards to security and privacy threats.
Owkin has also received ISO13485:2016 certification for the design, development, manufacturing, and distribution of its AI IVD diagnostic solutions. This certification highlights Owkin’s ability to deliver clinically robust solutions for unmet medical needs, developed with the highest quality and safety standards.
Owkin has raised $304.1m USD from investors such as Bpifrance Large Ventures, GV, NJF Capital, Cathay Innovation, F-Prime, Otium Capital, Eight Roads Ventures, Plug and Play, Mubadala and MACSF (French Pension Fund for Clinicians), as well as corporate institutional partners such as Sanofi and Bristol-Myers Squibb.
Funding Rounds
- Seed Round: $2.1M
- Series A: $72M
- Series B: $230M